Background: Genetic variations exist in the genes coding for the gluthatione S-transferases (GSTs) that may contribute to the variations in the metabolic breakdown of environmental carcinogenic and chemotherapeutic agents. Such metabolic variations are also considered to contribute to differences in interindividual susceptibility to cancer and disease outcome. Materials and Methods: In this study the GSTM1, GSTT1 and GSTP1 Ile105Val gene polymorphisms have been determined in a study population of one hundred Hungarian myeloma patients and their hospitalized controls. Results: There was no significant difference in the genotype frequencies between cases and controls, with a notable exception, that in the group of patients with GSTT1 homozygous deletion (null) genotype, no GSTP1 105Val/105Val homozygous variant genotype was detected. For the combined GSTT1/GSTM1 genotypes, the shortest mean survival was observed in the GSTT1 null /GSTM1 null genotype group of patients. The GSTP1 Val/Val homozygous variant genotype also appeared to be a risk factor for shortest survival time, however, these trends were not statistically significant. Conclusions: GST gene polymorphisms may have only a weak, if any, effect in the outcome of multiple myeloma, which could be confirmed by large-scale international molecular epidemiological studies.
|Title of host publication||Glutathione|
|Subtitle of host publication||Biochemistry, Mechanisms of Action and Biotechnological Implications|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||7|
|Publication status||Published - febr. 1 2013|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)